Sign in
Taking people in United StatesNo phase

Leg-worn nerve stimulation device for bowel problems after spinal cord injury

Tests a leg-worn stimulation device for constipation in adults with spinal cord injury.

Key facts

Who runs it
University of Michigan
Where
Ann Arbor, United StatesSee the site
Trial code
Registry title
Efficacy of a Wearable Noninvasive Neuromodulation Device
Status
Recruiting
People taking part
100 people, planned
Started
Jul 2026
Expected to end
Nov 2029
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • TNM at a sham-point (AccelBand) - randomized arm
  • TNM at a leg point (AccelBand)- randomized arm
  • TNM at a leg point (AccelBand)- open-label
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a spinal cord injury who have bowel problems caused by the injury, such as slow bowel movement and constipation. It tests a leg-worn device that sends mild electrical pulses through the skin.

Age
18 Years and older
Sex
All sexes can join
Disease stage
Spinal cord injury, caused by trauma or not, above the twelfth chest vertebra (T12). The injury must be incomplete, graded AIS B, C or D. The injury happened at least 6 months ago. Bowel problems caused by the injury.
Earlier treatment
People who had gut surgery cannot join, except simple appendix removal, gallbladder removal or caesarean section. People with implanted devices for electrical stimulation cannot join.
Biomarker or test result
At least one of the lower spinal reflexes must still be present: bulbocavernosus, patella or Achilles. Some feeling in the leg must remain.

Main reasons for not taking part

  • Diabetes, active inflammatory bowel disease, or a severe mental illness now or in the past
  • Taking opioid pain medicines every day, or current substance abuse
  • An implanted electrical device, such as a heart pacemaker
  • Being pregnant or planning a pregnancy
  • Needing a breathing machine, or severe autonomic dysreflexia (sudden dangerous rises in blood pressure)

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Traumatic or non-traumatic spinal cord injury (SCI)
  • SCI level above the twelfth thoracic vertebra (T12)
  • SCI classified as Sensory Incomplete (AIS B), C, or D
  • Post-SCI time ≥ 6 months
  • Neurogenic bowel dysfunction (NBD) as a result of SCI
  • Willing to sign the informed consent form

Who cannot take part

  • Prior gastrointestinal surgeries other than uncomplicated appendectomies, cholecystectomy or cesarean sections
  • Taking opioid medications on a regular daily basis
  • Significant cognitive impairment, impeding the ability to provide informed consent or complete the questionnaire
  • Known diagnosis of diabetes mellitus
  • Known current or past severe significant psychiatric disorder
  • Implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)
  • Active inflammatory bowel disease
  • Known current substance abuse
  • Currently pregnant or actively planning a pregnancy
  • Ventilator dependency
  • Severe autonomic dysreflexia
  • No preservation of the sacral spinal reflexes: bulbocavernosus, patella, or Achilles
  • Complete absence of sensation in the leg (since it is needed for calibrating the TNM intensity)

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Caitlin FisherTaking people

About the trial

What the trial wants to find out

The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI.

Read full original descriptionShow less

The study hypotheses:

* The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment. * The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.

The 2 groups in the trial

  • Sham (TNM at a sham-point) -Randomized armSham treatment, for comparison

    Participants will have a 2-week phase-in period.followed by a 4-week sham treatment. Sham participants can elect to have 2 weeks of open-label treatment once unblinded after 4 weeks of sham.

    Treatment: TNM at a sham-point (AccelBand) - randomized arm and TNM at a leg point (AccelBand)- open-label

  • Transcutaneous neuromodulation (TNM) at a leg point-Randomized armTreatment being tested

    Participants will have a 2-week phase-in period followed by a 4-week treatment phase.

    Treatment: TNM at a leg point (AccelBand)- randomized arm

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Early Feasibility Study of Using the AccelBand, a Leg-worn Transcutaneous Neuromodulation (TNM) Device, for Neurogenic Bowel Dysfunction (NBD) in People With Spinal Cord Injury (SCI)
Plain-language title
Leg-worn nerve stimulation device for bowel problems after spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
6 July 2026